CSIMC Recommends NHI Price Listing for 15 APIs/20 Products

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story


High Hopes for New Osteoporosis Drugs, but “Treatment Gap” Needs to Be Addressed


3 price-band (bracket) grouping rule:

The Column

Ask a Question and Shut Up


Takeda, Teva Hook Up to Form Generic Joint Venture in Japan(Nov.30)
PAFSC 1st Committee Gives Nod to Japan’s First PCSK9 Inhibitor(Nov.30)
Eisai to Venture into Chinese Generic Market by Acquiring Local Firm(Nov.30)
Takeda’s MS Drug Copaxone Now Available; Actelion to Release Japan’s 1st Pediatric PAH Medicine in January(Nov.30)
JCR to Launch Cell Therapy for Post-Transplant Complication in February(Nov.30)

News Calendar